Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × Amsacrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 4 Leukemia, Myeloid, Acute 3 Neutropenia 2 Leukemia, Myelomonocytic, Acute 2 Leukemia, Monocytic, Acute 2 Leukemia, Megakaryoblastic, Acute 2 Leukemia, Erythroblastic, Acute 2 Recurrence 1 Myelodysplastic Syndromes 1 Leukemia, Promyelocytic, Acute 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Dexamethasone 21 Rituximab 13 Paclitaxel 10 Gemcitabine 10 Cisplatin 10 pomalidomide 9 Lenalidomide 9 Carboplatin 8 Bortezomib 8 Cyclophosphamide 7 Drug Therapy 5 Cytarabine 5 selinexor 4 daratumumab 4 carfilzomib 4 Temozolomide 4 Doxorubicin 4 Docetaxel 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 ibrutinib 3 Vincristine 3 Prednisone 3 Cetuximab 3 Calcium Dobesilate 3 galiximab 2 eculizumab 2 durvalumab 2 blinatumomab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03765541 2025-04-10

DEXAML-03

University Hospital, Toulouse

Phase 3 Terminated

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡